Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
RESEARCH TRIANGLE PARK, N.C., April 24, 2017 -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its first quarter 2017 financial results will be reported on Thursday, May 4th, 2017.
BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss financial results and to provide an update regarding the Company’s clinical development programs. The call will be led by Jon P. Stonehouse, President & Chief Executive Officer, Thomas R. Staab II, Senior Vice President & Chief Financial Officer, and Dr. Bill Sheridan, Senior Vice President and Chief Medical Officer.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst currently has several ongoing development programs: BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema, and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is a potential treatment for filoviruses. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst’s first approved product and is currently marketed in the U.S., Japan, Taiwan and Korea. Post-marketing commitment development activities are ongoing, as well as activities to support regulatory approvals in other territories. For more information, please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
CONTACT: Robert Bennett, BioCryst Pharmaceuticals, +1-919-859-7910
